Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
fianlimab (REGN3767)
i
Other names:
REGN3767, REGN 3767, anti-LAG-3 MoAb REGN3767, REGN-3767
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(2)
News
Trials
Company:
Regeneron, Sanofi
Drug class:
LAG-3 inhibitor
Related drugs:
‹
MGD013 (5)
nivolumab/relatlimab-rmbw (4)
MK-4280 (2)
IBI110 (2)
FS118 (1)
BMS-986016 (1)
ABL501 (0)
CB213 (0)
EMB-02 (0)
GB266 (0)
GLS-012 (0)
HLX26 (0)
IBI-323 (0)
INCA32459 (0)
SHR-1802 (0)
Sym022 (0)
TNRX-257 (0)
ZGGS15 (0)
LBL-007 (0)
XmAb22841 (0)
TSR-033 (0)
MK-4280A (0)
LAG525 (0)
BI 754111 (0)
RG6139 (0)
INCAGN2385 (0)
MGD013 (5)
nivolumab/relatlimab-rmbw (4)
MK-4280 (2)
IBI110 (2)
FS118 (1)
BMS-986016 (1)
ABL501 (0)
CB213 (0)
EMB-02 (0)
GB266 (0)
GLS-012 (0)
HLX26 (0)
IBI-323 (0)
INCA32459 (0)
SHR-1802 (0)
Sym022 (0)
TNRX-257 (0)
ZGGS15 (0)
LBL-007 (0)
XmAb22841 (0)
TSR-033 (0)
MK-4280A (0)
LAG525 (0)
BI 754111 (0)
RG6139 (0)
INCAGN2385 (0)
›
Associations
(2)
News
Trials
Filter by
Latest
8d
CLeAR: Cemiplimab +/- Fianlimab Post Y90 Radioembolization in Patients With Hepatocellular Carcinoma (clinicaltrials.gov)
P1, N=20, Not yet recruiting, Virginia Commonwealth University
8 days ago
New P1 trial
|
CD4 (CD4 Molecule)
|
Libtayo (cemiplimab-rwlc) • fianlimab (REGN3767)
12d
HARMONY LUNG-2: A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer (clinicaltrials.gov)
P2/3, N=950, Active, not recruiting, Regeneron Pharmaceuticals | Recruiting --> Active, not recruiting
12 days ago
Enrollment closed • IO biomarker
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
cisplatin • carboplatin • paclitaxel • pemetrexed • Libtayo (cemiplimab-rwlc) • fianlimab (REGN3767)
12d
HARMONY LUNG-1: A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
P2/3, N=850, Active, not recruiting, Regeneron Pharmaceuticals | Recruiting --> Active, not recruiting
12 days ago
Enrollment closed
|
PD-L1 (Programmed death ligand 1)
|
Libtayo (cemiplimab-rwlc) • fianlimab (REGN3767)
18d
A Trial of Locoregionally Advanced Squamous Cell Carcinoma of The Head and Neck (clinicaltrials.gov)
P2, N=90, Not yet recruiting, University of Chicago
18 days ago
New P2 trial
|
carboplatin • paclitaxel • Libtayo (cemiplimab-rwlc) • fianlimab (REGN3767)
22d
A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery (clinicaltrials.gov)
P2, N=195, Active, not recruiting, Regeneron Pharmaceuticals | Recruiting --> Active, not recruiting
22 days ago
Enrollment closed
|
PD-L1 (Programmed death ligand 1)
|
cisplatin • carboplatin • paclitaxel • pemetrexed • Libtayo (cemiplimab-rwlc) • fianlimab (REGN3767)
1m
R3767-ONC-2011: Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma (clinicaltrials.gov)
P3, N=1546, Active, not recruiting, Regeneron Pharmaceuticals | Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2025 --> Mar 2026
1 month ago
Enrollment closed • Trial primary completion date
|
Keytruda (pembrolizumab) • Libtayo (cemiplimab-rwlc) • fianlimab (REGN3767)
2ms
A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov)
P2, N=120, Not yet recruiting, Regeneron Pharmaceuticals | Trial completion date: Nov 2029 --> Dec 2030 | Initiation date: Mar 2025 --> Mar 2026 | Trial primary completion date: Apr 2027 --> Jun 2028
2 months ago
Trial completion date • Trial initiation date • Trial primary completion date • IO biomarker
|
PD-L1 (Programmed death ligand 1)
|
Libtayo (cemiplimab-rwlc) • fianlimab (REGN3767)
2ms
Capecitabine/Oxaliplatin Chemotherapy and Cemiplimab With or Without Fianlimab or REGN7075 in Locally Advanced Rectal Cancer (clinicaltrials.gov)
P2, N=66, Not yet recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2 months ago
New P2 trial
|
capecitabine • oxaliplatin • Libtayo (cemiplimab-rwlc) • fianlimab (REGN3767)
3ms
LAG-MAPS: Trial Assessing Fianlimab Plus Cemiplimab Plus Chemotherapy or Cemiplimab Plus Chemotherapy in Patients With Pleural Mesothelioma (clinicaltrials.gov)
P2, N=126, Not yet recruiting, Intergroupe Francophone de Cancerologie Thoracique
3 months ago
New P2 trial
|
cisplatin • carboplatin • pemetrexed • Libtayo (cemiplimab-rwlc) • fianlimab (REGN3767)
3ms
A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery (clinicaltrials.gov)
P2, N=180, Recruiting, Regeneron Pharmaceuticals | Trial completion date: Apr 2029 --> Nov 2029 | Trial primary completion date: Sep 2025 --> May 2026
3 months ago
Trial completion date • Trial primary completion date
|
cisplatin • carboplatin • paclitaxel • pemetrexed • Libtayo (cemiplimab-rwlc) • fianlimab (REGN3767)
3ms
LAG-BOOST: Cemiplimab or Cemiplimab and Fianlimab After Stereotactic Body Radiotherapy in Clear Cell Renal Cell Carcinoma (clinicaltrials.gov)
P2, N=72, Not yet recruiting, University of Oklahoma
3 months ago
New P2 trial
|
Libtayo (cemiplimab-rwlc) • fianlimab (REGN3767)
5ms
A Study Comparing Two Immunotherapy Options for Human Papillomavirus Positive HPV-Positive Head and Neck Cancer After Treatment (clinicaltrials.gov)
P2, N=68, Not yet recruiting, University of Chicago
5 months ago
New P2 trial • Minimal residual disease
|
Libtayo (cemiplimab-rwlc) • fianlimab (REGN3767)
Share via
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.